TMCnet News
FDA Twitter guidance a gradual step [Medical Marketing and Media](Medical Marketing and Media Via Acquire Media NewsEdge) FDA'S social media and "cor- recting independent third-party information" draft guidance was greeted as a gradual-but impor- tant-step in the right direction for marketers to deploy their digital and social tools without fear of a Warning Letter. In its 15-page recommenda- tions for Twitter, the agency says companies should rely on "material fact," as in supported indications from a product's ISI, and that benefits should be juxtaposed with the drug's limitations, contraindications or its relevant patient population- and the most serious side effects should be the most prominent. In another document, FDA discussed how to handle misin- formation by third parties. "Be non-promotional in nature," the regulator bulleted. Don't just limit corrections to misinformation that show a prod- uct in a negative light, the guid- ance adds. It recommends firms keep records of these exchanges. -Kevin McCaffrey (c) 2014 Haymarket Media, Inc. |